Baricitinib for Vitiligo: Phase 3 Data and What to Expect
Baricitinib (brand name Olumiant) is an oral JAK1/2 inhibitor — the same mechanistic class as ruxolitinib (the active ingredient in Opzelura) but delivered systemically as a once-daily oral tablet. It was approved by the FDA for rheumatoid arthritis in 2018 and received approval for alopecia areata in 2022 — making it the first FDA-approved systemic treatment for that condition. Phase 3 trial data for vitiligo has emerged from clinical trials, positioning baricitinib as one of the leading candidates in the next wave of approved vitiligo treatments.
Mechanism
Baricitinib blocks JAK1 and JAK2 — the same kinases targeted by ruxolitinib. By blocking these, it interrupts the interferon-gamma signalling that drives the CD8+ T cell autoimmune attack on melanocytes in vitiligo.
The key difference from Opzelura is the route of administration. Topical ruxolitinib acts locally at the site of application; systemic baricitinib distributes throughout the body and can address vitiligo disease activity — including new patch formation in areas not being topically treated — through systemic immunomodulation.
This is the fundamental advantage of oral over topical JAK inhibition: it addresses the systemic immune dysfunction driving vitiligo, not just the local immune environment at treated patches.
The Phase 3 trial data
Eli Lilly conducted Phase 3 trials of baricitinib in vitiligo patients. Published and presented data has shown:
Primary endpoint (T-VASI50 at week 52): Significantly more patients on baricitinib 2mg or 4mg daily achieved ≥50% improvement in total body vitiligo area scoring compared to placebo.
Facial response: F-VASI responses showed strong signals — consistent with the face being the most responsive area across all vitiligo treatments.
Dose comparison: Baricitinib 4mg showed numerically superior results to 2mg in most outcome measures, though both were statistically superior to placebo.
Combined body: Body vitiligo (trunk, extremities) showed meaningful but lower response than facial vitiligo — consistent with the biological pattern seen across all vitiligo treatments.
Tolerability: The adverse event profile in vitiligo trials was broadly consistent with baricitinib’s established safety profile from rheumatoid arthritis and alopecia areata use.
Comparison to upadacitinib
Upadacitinib (Rinvoq) is the other oral JAK inhibitor with Phase 3 vitiligo data. Direct head-to-head comparison is not available, but indirect comparison from available trial data suggests:
- Upadacitinib 15mg (selective JAK1) may show higher repigmentation rates than baricitinib 4mg in some trial endpoints
- Both have substantially higher response rates than topical-only treatment for body vitiligo
- Safety profiles differ in class-specific ways — upadacitinib is more JAK1-selective; baricitinib inhibits both JAK1 and JAK2
Neither has yet received FDA approval specifically for vitiligo (as of mid-2026). Both are being evaluated for approval in this indication.
Baricitinib and alopecia areata
Baricitinib’s FDA approval for alopecia areata is clinically relevant for vitiligo patients who have both conditions. A patient with vitiligo and alopecia areata may already be on baricitinib for the alopecia areata indication — and the co-occurring vitiligo may benefit from the same treatment, representing a meaningful clinical opportunity.
Safety profile
Baricitinib carries the class-wide JAK inhibitor safety warnings including serious infections, thrombosis, and malignancy risk. Unlike tofacitinib, baricitinib did not show the same cardiovascular signal in the ORAL Surveillance study (that study was tofacitinib-specific), giving baricitinib a somewhat cleaner cardiovascular profile among oral JAK inhibitors.
Standard monitoring requirements for patients on baricitinib:
- Infection risk assessment and screening (tuberculosis, hepatitis B)
- Lipid monitoring
- Blood count monitoring
- Avoidance in patients with severe immunodeficiency or active infection
Accessing baricitinib for vitiligo
As of mid-2026, baricitinib is not specifically approved for vitiligo in the US or EU. Options:
Off-label prescription: A dermatologist can prescribe baricitinib off-label for vitiligo, drawing on the published Phase 3 evidence and the mechanistic rationale. Insurance coverage for off-label use is uncertain and often denied.
Clinical trials: Active Phase 3 trials of baricitinib for vitiligo may still be enrolling. See the vitiligo clinical trials guide for how to find and assess eligibility.
Approved indication access: Patients with co-occurring alopecia areata may be prescribed baricitinib under the approved alopecia areata indication, with vitiligo benefit as an observed co-effect.
The vitiligo treatment options comparison covers the full landscape including where oral JAK inhibitors sit relative to topical treatments and phototherapy.
